Alkalinized lidocaine/heparin - Hyloris Pharmaceuticals/Vaneltix Pharma
Alternative Names: Alenura; Alkalinized lidocaine HCl and heparin sodium; alkalinized lidocaine HCl/Heparin sodium; Heparin/alkalinized lidocaine - Hyloris Pharmaceuticals/Vaneltix Pharma; Lidocaine/heparin - Hyloris Pharmaceuticals/Vaneltix Pharma; VNX 004; VNX-001Latest Information Update: 09 Jun 2023
At a glance
- Originator Vaneltix Pharma
- Developer Hyloris Pharmaceuticals; Vaneltix Pharma
- Class Acetanilides; Analgesics; Anti-infectives; Anti-inflammatories; Antithrombotics; Class Ib antiarrhythmics; Heparins; Local anaesthetics; Mucolytics; Non-opioid analgesics; Small molecules
- Mechanism of Action Cell adhesion molecule inhibitors; Deoxyribonuclease I stimulants; Factor Xa inhibitors; Glycosaminoglycan stimulants; Heparanase inhibitors; Inflammation mediator inhibitors; Sodium channel antagonists; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute pain; Interstitial cystitis
Most Recent Events
- 22 May 2023 Phase-II clinical trials in Interstitial cystitis in USA (Intravesicular) (NCT05737121)
- 28 Feb 2023 Vaneltix Pharma plans a phase II trial for Pain in USA (Intravesicular) in March 2023 (NCT05737121)
- 09 Mar 2022 Preclinical trials in Acute pain in USA (Topical) (Vaneltix Pharma pipeline, February 2022)